Drugs.com - Clinical Trials

SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis

OSAKA, Japan, March 13, 2025 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral presentation at the Conference of...

Mar 18, 2025 - 07:11
 0
SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis
OSAKA, Japan, March 13, 2025 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral presentation at the Conference of...
Read More

Tags:

Previous Article

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Po...

Next Article

8 Luxury Cars Of 2025 That Burn Rubber & Spark Joy

Related Posts

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

First Clinical Data for Gilead’s Investigational Once-Y...

Mar 11, 2025  0

Icotrokinra Results Show Potential to Set a New Standard of Treatment in Plaque Psoriasis

Icotrokinra Results Show Potential to Set a New Standar...

Mar 9, 2025  0

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease

Johnson & Johnson’s Posdinemab and Tau Active Immunothe...

Feb 9, 2025  0